Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

Careers

Publications

Lotilaner Ophthalmic Solution, 0.25% for Meibomian Gland Disease in Patients With Demodex Blepharitis

View Poster

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2)

View Article

Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies

View Article

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials

View Article

Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study

View Article

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% in the Treatment of Demodex Blepharitis: A Systematic Review and 
Meta-Analysis

View Article

A Systematic Review and Meta-Analysis of the Safety and Efficacy of 0.25% Lotilaner Ophthalmic Solution in the Treatment of Demodex Blepharitis

View Article

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis

View Article

Treatment of Demodex Blepharitis: 
A Prospective, Randomized, Controlled, 
Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% 
Eyedrops to Vehicle

View Article

Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex Blepharitis

View Article

Our Terms of Use and Privacy Policy have changed.

By clicking accept, you agree that you have read and will abide by these new terms.